Cargando…

Three years of treatment with minodronate in patients with postmenopausal osteoporosis

The objective of this study was to determine the safety and efficacy of long-term minodronate treatment in women with postmenopausal osteoporosis based on re-analysis of a phase III 2-year clinical trial with a 1-year extension. Women aged 55–80 years old with fragility fractures were enrolled and r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagino, Hiroshi, Shiraki, Masataka, Fukunaga, Masao, Nakano, Tetsuo, Takaoka, Kunio, Ohashi, Yasuo, Nakamura, Toshitaka, Matsumoto, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396350/
https://www.ncbi.nlm.nih.gov/pubmed/22134624
http://dx.doi.org/10.1007/s00774-011-0332-2
_version_ 1782238104812257280
author Hagino, Hiroshi
Shiraki, Masataka
Fukunaga, Masao
Nakano, Tetsuo
Takaoka, Kunio
Ohashi, Yasuo
Nakamura, Toshitaka
Matsumoto, Toshio
author_facet Hagino, Hiroshi
Shiraki, Masataka
Fukunaga, Masao
Nakano, Tetsuo
Takaoka, Kunio
Ohashi, Yasuo
Nakamura, Toshitaka
Matsumoto, Toshio
author_sort Hagino, Hiroshi
collection PubMed
description The objective of this study was to determine the safety and efficacy of long-term minodronate treatment in women with postmenopausal osteoporosis based on re-analysis of a phase III 2-year clinical trial with a 1-year extension. Women aged 55–80 years old with fragility fractures were enrolled and randomized to take 1 mg minodronate or placebo once a day in the original 2-year study. The subjects who completed the 2-year study were invited to participate in an additional 1-year extension in which all subjects were to receive minodronate. Finally, a total 380 subjects completed the extension study (186 from the placebo group and 194 from the minodronate group). Fracture results observed in the extension study were consistent with those observed in the first 2 years in minodronate group. In contrast, the placebo/minodronate group showed a decreased incidence of new vertebral fractures during year 3 compared to that in year 2. In the patients who received minodronate in the original 2-year study, lumbar bone mineral density (BMD) increased consistently during year 3 and bone turnover markers decreased within the first 6 months and remained constant thereafter over 3 years. Similar positive effects of minodronate on BMD and bone turnover markers occurred when therapy was initiated in the placebo/minodronate group. No new safety concerns observed during the extension period compared to the safety observations made during the 2-year study. It was concluded that daily administration of 1 mg oral minodronate is safe and well tolerated, and that the efficacy of this dose in reducing vertebral fracture risk in postmenopausal women over 2 years is sustained with continuing treatment.
format Online
Article
Text
id pubmed-3396350
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-33963502012-07-17 Three years of treatment with minodronate in patients with postmenopausal osteoporosis Hagino, Hiroshi Shiraki, Masataka Fukunaga, Masao Nakano, Tetsuo Takaoka, Kunio Ohashi, Yasuo Nakamura, Toshitaka Matsumoto, Toshio J Bone Miner Metab Original Article The objective of this study was to determine the safety and efficacy of long-term minodronate treatment in women with postmenopausal osteoporosis based on re-analysis of a phase III 2-year clinical trial with a 1-year extension. Women aged 55–80 years old with fragility fractures were enrolled and randomized to take 1 mg minodronate or placebo once a day in the original 2-year study. The subjects who completed the 2-year study were invited to participate in an additional 1-year extension in which all subjects were to receive minodronate. Finally, a total 380 subjects completed the extension study (186 from the placebo group and 194 from the minodronate group). Fracture results observed in the extension study were consistent with those observed in the first 2 years in minodronate group. In contrast, the placebo/minodronate group showed a decreased incidence of new vertebral fractures during year 3 compared to that in year 2. In the patients who received minodronate in the original 2-year study, lumbar bone mineral density (BMD) increased consistently during year 3 and bone turnover markers decreased within the first 6 months and remained constant thereafter over 3 years. Similar positive effects of minodronate on BMD and bone turnover markers occurred when therapy was initiated in the placebo/minodronate group. No new safety concerns observed during the extension period compared to the safety observations made during the 2-year study. It was concluded that daily administration of 1 mg oral minodronate is safe and well tolerated, and that the efficacy of this dose in reducing vertebral fracture risk in postmenopausal women over 2 years is sustained with continuing treatment. Springer Japan 2011-12-02 2012-07 /pmc/articles/PMC3396350/ /pubmed/22134624 http://dx.doi.org/10.1007/s00774-011-0332-2 Text en © The Japanese Society for Bone and Mineral Research and Springer 2011
spellingShingle Original Article
Hagino, Hiroshi
Shiraki, Masataka
Fukunaga, Masao
Nakano, Tetsuo
Takaoka, Kunio
Ohashi, Yasuo
Nakamura, Toshitaka
Matsumoto, Toshio
Three years of treatment with minodronate in patients with postmenopausal osteoporosis
title Three years of treatment with minodronate in patients with postmenopausal osteoporosis
title_full Three years of treatment with minodronate in patients with postmenopausal osteoporosis
title_fullStr Three years of treatment with minodronate in patients with postmenopausal osteoporosis
title_full_unstemmed Three years of treatment with minodronate in patients with postmenopausal osteoporosis
title_short Three years of treatment with minodronate in patients with postmenopausal osteoporosis
title_sort three years of treatment with minodronate in patients with postmenopausal osteoporosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396350/
https://www.ncbi.nlm.nih.gov/pubmed/22134624
http://dx.doi.org/10.1007/s00774-011-0332-2
work_keys_str_mv AT haginohiroshi threeyearsoftreatmentwithminodronateinpatientswithpostmenopausalosteoporosis
AT shirakimasataka threeyearsoftreatmentwithminodronateinpatientswithpostmenopausalosteoporosis
AT fukunagamasao threeyearsoftreatmentwithminodronateinpatientswithpostmenopausalosteoporosis
AT nakanotetsuo threeyearsoftreatmentwithminodronateinpatientswithpostmenopausalosteoporosis
AT takaokakunio threeyearsoftreatmentwithminodronateinpatientswithpostmenopausalosteoporosis
AT ohashiyasuo threeyearsoftreatmentwithminodronateinpatientswithpostmenopausalosteoporosis
AT nakamuratoshitaka threeyearsoftreatmentwithminodronateinpatientswithpostmenopausalosteoporosis
AT matsumototoshio threeyearsoftreatmentwithminodronateinpatientswithpostmenopausalosteoporosis